A Phase 4 interventional study of Dupilumab and Placebo in Atopic Dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Terminated at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-04.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 26th largest by enrollment, is one of 5 that started in 2018, is one of 24 in phase 4, and was the 21st registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,448 studies on the registry; 180 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 302 (74%) have results posted.
35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID): 8 open now, 9 under way, none of them phase 3. Of 26 finished, 8 (31%) have results posted.
Among the 35 studies in Dermatitis, Atopic by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 4, and was the 25th registered.
National Institute of Allergy and Infectious Diseases (NIAID)’s Dermatitis, Atopic studies by the year they started, since 1996.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among National Institute of Allergy and Infectious Diseases (NIAID)’s 35 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the effect that T helper 2 (Th2) blockade has on well-described pathophysiological features of Atopic Dermatitis (AD), for example: barrier, epidermal activation, dysbiosis and epidermal lipids.
This is a multi-center, randomized, double-masked, placebo-controlled trial investigating the effect of 6 weeks of dupilumab treatment on quantitative and qualitative measures of cutaneous microbial community structure, skin barrier biology, and circulating T cell profiles, in adults with chronic moderate-to-severe atopic dermatitis (AD).
After obtaining informed consent, eligible participants will return to clinic for their Treatment Initiation Visit (Day 0) and will be randomized 2:1 active to placebo. Participants will receive three doses of dupilumab or placebo based on their randomization assignment. The first dose (600 mg loading dose of dupilumab or placebo) will be administered on Day 0 and the second and third doses (300 mg dupilumab or placebo) on Day 14 and Day 28, respectively.
Participants will return to clinic on Days 3, 7, and 21 during the double-masked portion of the study. Participants will begin the open-label extension (OLE) at Day 42 and will receive dupilumab (600 mg loading dose [two 300 mg injections] for those initially randomized to the placebo group and a 300 mg dose plus placebo injection for those initially randomized to the dupilumab group). Participants will return to clinic on Days 77 and 112 during the OLE portion of the study. During all visits (Day 0-Day 112), Adverse Events (AEs), concomitant medications, and medical history will be assessed and physical exams including assessment of AD severity will be performed. Blood, urine, skin swabs, skin tape strips, and skin biopsies, as applicable, will be collected, and barrier assessments will be performed per the Schedule of Events, per protocol. Samples will be collected prior to dupilumab or placebo administration on Days 0, 14, 28, and 42. After Day 112, a follow-up call (Day 182) will be made to assess for pregnancy, current medications, and adverse events (AEs).
If concerns arise between regularly scheduled visits, participants will be instructed to contact study personnel and may be asked to return to the study site for an "Unscheduled Visit." Participants may be asked to return for Unscheduled Visits, as needed for the duration of the study, to provide additional blood, skin swabs, skin tape strips, or skin biopsies,as applicable, for further mechanistic and functional studies, if biosamples are lost or destroyed, or if insufficient yields were obtained at a previous study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females with * and sexually active must agree to use FDA approved methods of for the duration of the study, including during the open-label and follow-up portions of the study:
--FDA approved methods of birth control include hormonal contraceptives, intrauterine device, double barrier contraception (i.e., condom plus diaphragm), or male partner with documented vasectomy.
---*Menopause is defined as at least 12 consecutive months without menses; if in question, a follicle stimulating hormone of ≥25 U/mL must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable; if documented, women with these conditions are not required to use additional contraception.
Exclusion Criteria:
Ocular disorder that, in the opinion of the investigator, could adversely affect the individual's risk for study participation. Examples include, but are not limited to, individuals with a history of or active case of:
Treatment with biologics as follows:
The following treatments within 4 weeks before the Treatment Initiation Visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the screening period and study treatment (i.e., Screening through Day 112):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28). Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98. The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose.
Drug: Dupilumab · Drug: Placebo
Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28). Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98. The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose.
Drug: Dupilumab · Drug: Placebo
Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
Also known as: Dupixent®, IL4Ra mAb
Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Also known as: Dupilumab placebo
Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Day 28, measurement is expressed in relative Colony Forming Units (rCFU)/cm\^2). The abundance of S. aureus is summarized as the geometric mean ratio (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The geometric mean ratio is reported from an ANCOVA model with fixed effects for clinical site, disease severity at Day 0 (as measured by EASI \>21.1 \[severe\] or ≤21.1 \[non-severe\]) and S. aureus abundance at Day 0.
Time frame: Day 28 (Post treatment initiation)
Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Days 0, 3, 7, 14, 21, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 42, 77 and 112
Staphylococcus Aureus Abundance on Non-lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on non-lesional skin at Days 0, 3, 7, 14, 21, 28, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on non-lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model estimated the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Transepidermal Water Loss (TEWL) of Non-lesional and Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
TEWL assessment is a noninvasive in vivo measurement of water loss across the stratum corneum that is used to characterize skin barrier function. Basal TEWL =baseline measure (prior to tape stripping). An increase in TEWL values shows damage to the skin barrier function. Basal TEWL was measured on non-lesional and lesional skin. Basal TEWL is summarized as the mean difference between the dupilumab and placebo arms. The mean difference is reported from two linear mixed models for repeated measures (lesional and non-lesional) with fixed effects for treatment arm, basal TEWL at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 3, 7, 14, 21, 28, and 42. Two linear mixed models similar to the models specified above were fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Transepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
TEWL skin barrier assessment was assessed prior to tape stripping and repeated after 5, 10, and 15 tape strips. TEWL AUC was calculated using the trapezoidal rule and represents skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL AUC was measured on non-lesional skin at Days 0, 7, 14, 21, 28, 42, 77 and 112. The mean difference (between Groups) is reported from a linear mixed model for repeated measures with a random effect for participant and fixed effects for treatment arm, TEWL AUC at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 7, 14, 21, 28, and 42. A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the mean difference within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
Time frame: Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112
Transepidermal Water Loss (TEWL) Slope on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
The skin tape strip collection was comprised of 1 set of 15 strips from non-lesional skin and was collected as part of the TEWL skin barrier assessment. The TEWL values measured at every 5 tape strips were used to model the TEWL slope. TEWL slope assesses skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL slope is summarized as the mean difference (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The mean difference in slope for each Day is reported from a linear mixed model for repeated measures with a fixed effects for basal TEWL prior to tape stripping, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, tape strip number, and an interaction term between treatment arm and tape strip number.
Time frame: Day 0 (Prior to treatment), 7, 14, 21, 28, 42, 77 and 112
Eczema Area and Severity Index (EASI) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
EASI is a composite score (range: 0-72) measuring physical signs of atopic dermatitis, including area of involvement and severity. Severity components include: erythema, papulation, excoriation and lichenification \[0=absent, 1=mild, 2=moderate, 3=severe\] for each body region (head/neck, trunk, arms, legs). Area of involvement (%) is assessed for each body region. Area and severity of each body region is weighted based on size of region, and region scores are added for the total score. Scores ≤7 are considered mild, \>7 and ≤21 are considered moderate, and \>21 are considered severe. The mean EASI score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for EASI at Day 0, treatment arm, clinical site, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s), Additionally, a similar model was fit using all time points.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Investigator Global Assessment (IGA) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Investigator Global Assessment (IGA) score is a subjective scale measuring disease severity. Based on a 5-point scale from 0 (completely clear) to 4 (severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. The mean IGA score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for IGA at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
SCORing Atopic Dermatitis (SCORAD) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
SCORAD is a composite index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments of itch and sleep loss \[itch: 0 (no itch) to 10 (worst itch imaginable) / sleep loss: 0 (no sleep loss) to 10 (worst imaginable sleep loss)\], and c) 6 disease intensity assessments \[dryness, erythema, edema/papulation, excoriation, lichenification and oozing/crusting, each graded from 0-3: 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The score ranges from 0 (no AD present) to 103 (severe). The mean SCORAD score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for SCORAD at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
Pruritus Numerical Rating Scale (Pruritus NRS) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up
Pruritus NRS scale is an assessment tool that is used to report the average intensity of a participant's pruritus (itch) during a 24-hour recall period. Participants were asked to report the average itch experienced during the past 24 hours on a scale of 0 - 10 \[0= no itch; 10= worst imaginable itch\]). The mean Pruritus NRS score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for Pruritus NRS at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
Time frame: Day 0 (Prior to treatment), 3, 7, 14, 21, 28, 42, 77 and 112
EXPLORATORY: Composition of Bacterial Taxa
16S rRNA microbiome data (e.g., bacterial sequence reads) will be employed to identify changes in community composition and diversity at lesional and non-lesional skin sites prior to and throughout dupilumab or placebo treatment.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Abundance of Bacterial Taxa in Lesional and Non-lesional Skin
The aim is to assess the effect of dupilumab on the skin transcriptome in lesional and non-lesional skin. Inclusion in this exploratory aim is restricted to non-University of Rochester Medical Center study participants only.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Gene Expression in the Skin Transcriptome in Non-lesional Skin
The aim is to assess the effect of dupilumab on gene expression in the skin transcriptome of non-lesional skin.
Time frame: Day 0 (Prior to treatment) and 7
EXPLORATORY: Gene Expression in the Skin Transcriptome in Lesional Skin
The aim is to assess the effect of dupilumab on the gene expression in the skin transcriptome of lesional skin.
Time frame: Day 0 (Prior to treatment), 7, and 21
EXPLORATORY: Lipid Profiles of Non-Lesional and Lesional Skin
The aim is to assess the effect of dupilumab on lipids, which play a role in the skin barrier, will be extracted from the skin tape strips and measured using mass spectrometry methodology. Skin tape strip method allows characterization of components of the epidermis, dermis, and immune cells present in the skin.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Expression of S. Aureus Superantigens and Toxins on Lesional and Non-Lesional Skin
The aim is to assess the effect of dupilumab on the expression of the bacterium Staphylococcus aureus (S. aureus) superantigens and toxins on lesional and non-lesional skin.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Confocal Imaging of Tight Junctions and Relationship to LCs in the Epidermis From Non-Lesional Skin
The aim is to assess the effect of dupilumab on non-lesional skin barrier structure and Langerhans cells (LC) by confocal imaging. Inclusion in this exploratory aim is limited to University of Rochester Medical Center study participants.
Time frame: Days 0 (Prior to treatment), 7 and 21
EXPLORATORY: Percent of Coagulase-Negative Staphylococci [CoNS] Isolates That Kill S. Aureus on Lesional and Non-Lesional Skin
The aim is to assess the effect of dupilumab on the function of the skin microbiome (e.g., the ability of Coagulase-negative staphylococci isolates \[CoNS\] to kill S. aureus) in lesional and non-lesional skin.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Peripheral Blood Mononuclear Cells (PBMCs) Immunoprofiling
The aim is to assess the effect of dupilumab on PBMC immunoprofiles.Flow cytometry analysis will be performed on PBMCs, using phenotyping panels to identify resting leukocyte populations, as well as T cell responses to antigens and myeloid responses to Toll-like receptor (TLR) ligands.
Time frame: Days 0 (Prior to treatment), 14 and 28
EXPLORATORY: Levels of Serum Biomarkers (e.g. Th2 Biomarkers)
The aim is to assess the effect of dupilumab on serum biomarkers (e.g. T helper type 2 \[Th2\] biomarkers).
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: Levels of Serum Anti-Drug Antibodies (ADA)
The presence of anti-drug antibodies will be assessed and compared between intervention groups.
Time frame: Day 0 (Prior to treatment), 16 weeks
EXPLORATORY: The Presence of Single Nucleotide Polymorphisms (SNPs)
Towards discovery and replication of susceptibility loci in atopic dermatitis pathogenesis.
Time frame: Day 0 (Prior to treatment)
72 participants were randomized from July 2018 to March 2020 from 9 clinical sites.First participant enrollment occurred on July 25, 2018.
| Milestone | Dupilumab | Placebo | Dupilumab to Open-Label Extension Dupilumab | Placebo to Open-Label Extension Dupilumab |
|---|---|---|---|---|
| Started | 46 | 26 | 0 | 0 |
| Completed | 45 | 26 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Dupilumab | Placebo | Dupilumab to Open-Label Extension Dupilumab | Placebo to Open-Label Extension Dupilumab |
|---|---|---|---|---|
| Started | 0 | 0 | 45 | 26 |
| Completed | 0 | 0 | 41 | 25 |
| Not completed | 0 | 0 | 4 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Participant moved | 0 | 0 | 1 | 0 |
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Day 28, measurement is expressed in relative Colony Forming Units (rCFU)/cm\^2). The abundance of S. aureus is summarized as the geometric mean ratio (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The geometric mean ratio is reported from an ANCOVA model with fixed effects for clinical site, disease severity at Day 0 (as measured by EASI \>21.1 \[severe\] or ≤21.1 \[non-severe\]) and S. aureus abundance at Day 0.
| Relative Colony Forming Unit (rCFU)/cm^2 | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up | 86.01 (34.07 to 217.11) | 2608.4 (835.02 to 8147.99) |
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on lesional skin at Days 0, 3, 7, 14, 21, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
| Relative Colony Forming Unit (rCFU)/cm^2 | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 833.82 (411.45 to 1689.74) | 3028.88 (1256.63 to 7300.56) |
| Day 7 | 337.48 (138.69 to 821.16) | 900.59 (290.95 to 2787.59) |
| Day 14 | 205.06 (91.16 to 461.27) | 2690.79 (964.61 to 7505.96) |
| Day 21 | 179.91 (80.71 to 401.02) | 2468.64 (916.89 to 6646.62) |
| Day 42 | 177.79 (79.02 to 400.05) | 1112.55 (409.02 to 3026.14) |
| Day 77 | 56.85 (20.44 to 158.08) | 150.81 (43.93 to 517.81) |
| Day 112 | 42.35 (14.91 to 120.28) | 174.19 (53.18 to 570.53) |
Staphylococcus aureus (S. aureus) abundance was measured by microbial DNA (femA qPCR) on non-lesional skin at Days 0, 3, 7, 14, 21, 28, 42, 77 and 112. The abundance of S. aureus is summarized as the geometric mean ratio (GMR) and corresponding 95% confidence interval between the dupilumab and placebo arms. The GMR is reported from a linear mixed model for repeated measures with fixed effects for S. aureus abundance on non-lesional skin at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement (as a categorical variable), and an interaction term between treatment arm and pre-specified time point(s). A linear mixed model similar to the model specified above was fit for every time point measured. The model estimated the GMR between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
| Relative Colony Forming Unit (rCFU)/cm^2 | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 221.75 (99.74 to 493.01) | 277.21 (100.25 to 766.52) |
| Day 7 | 143.19 (66.56 to 308.04) | 539.97 (201.61 to 1446.22) |
| Day 14 | 118.15 (57.86 to 241.27) | 326.55 (132.38 to 805.48) |
| Day 21 | 93.32 (44.33 to 196.46) | 128.56 (51.17 to 323.01) |
| Day 28 | 61.67 (29.55 to 128.72) | 369.74 (145.96 to 936.60) |
| Day 42 | 98.97 (44.01 to 222.55) | 191.30 (70.36 to 520.10) |
| Day 77 | 86.91 (32.27 to 234.09) | 182.19 (57.37 to 578.60) |
| Day 112 | 76.71 (27.37 to 214.99) | 146.35 (45.23 to 473.54) |
TEWL assessment is a noninvasive in vivo measurement of water loss across the stratum corneum that is used to characterize skin barrier function. Basal TEWL =baseline measure (prior to tape stripping). An increase in TEWL values shows damage to the skin barrier function. Basal TEWL was measured on non-lesional and lesional skin. Basal TEWL is summarized as the mean difference between the dupilumab and placebo arms. The mean difference is reported from two linear mixed models for repeated measures (lesional and non-lesional) with fixed effects for treatment arm, basal TEWL at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 3, 7, 14, 21, 28, and 42. Two linear mixed models similar to the models specified above were fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the ratio within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
| g/m^2/hour | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 - Lesional | 33.46 (28.52 to 38.39) | 42.99 (36.57 to 49.41) |
| Day 7 - Lesional | 40.08 (33.79 to 46.37) | 41.15 (32.70 to 49.61) |
| Day 14 - Lesional | 31.96 (27.19 to 36.74) | 31.49 (25.47 to 37.51) |
| Day 21 - Lesional | 28.14 (23.25 to 33.02) | 34.11 (27.74 to 40.48) |
| Day 28 - Lesional | 24.93 (19.97 to 29.89) | 32.03 (25.93 to 38.13) |
| Day 42 - Lesional | 25.34 (20.58 to 30.10) | 33.33 (27.46 to 39.19) |
| Day 77 - Lesional | 24.54 (18.94 to 30.13) | 25.58 (19.14 to 32.02) |
| Day 112 - Lesional | 22.99 (16.79 to 29.18) | 22.82 (15.87 to 29.78) |
| Day 3 - Non-lesional | 24.24 (20.87 to 27.60) | 23.55 (19.05 to 28.05) |
| Day 7 - Non-lesional | 22.58 (19.60 to 25.57) | 20.23 (16.28 to 24.18) |
| Day 14 - Non-lesional | 23.30 (19.90 to 26.71) | 23.20 (18.77 to 27.63) |
| Day 21 - Non-lesional | 19.55 (16.54 to 22.57) | 22.86 (18.78 to 26.95) |
| Day 28 - Non-lesional | 17.55 (15.08 to 20.03) | 19.31 (16.11 to 22.51) |
| Day 42 - Non-lesional | 16.95 (14.50 to 19.40) | 19.12 (16.17 to 22.07) |
| Day 77 - Non-lesional | 15.45 (12.60 to 18.29) | 17.55 (14.27 to 20.82) |
| Day 112 - Non-lesional | 13.97 (11.55 to 16.39) | 15.86 (13.05 to 18.68) |
TEWL skin barrier assessment was assessed prior to tape stripping and repeated after 5, 10, and 15 tape strips. TEWL AUC was calculated using the trapezoidal rule and represents skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL AUC was measured on non-lesional skin at Days 0, 7, 14, 21, 28, 42, 77 and 112. The mean difference (between Groups) is reported from a linear mixed model for repeated measures with a random effect for participant and fixed effects for treatment arm, TEWL AUC at Day 0, clinical site, and disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1 at Days 7, 14, 21, 28, and 42. A linear mixed model similar to the model specified above was fit for every time point measured. The model was used to estimate the mean difference between treatment arms at Days 77 and 112 and the mean difference within treatment arm between Day 77 and Day 42 and between Day 112 and Day 42.
| g/m^2/hour | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 7 | 527.79 (466.25 to 589.33) | 442.74 (363.86 to 521.62) |
| Day 14 | 504.80 (426.50 to 583.09) | 526.70 (424.66 to 628.74) |
| Day 21 | 451.40 (385.72 to 517.07) | 533.89 (444.83 to 622.96) |
| Day 28 | 390.92 (328.07 to 453.76) | 483.02 (405.23 to 560.81) |
| Day 42 | 397.22 (341.24 to 453.20) | 445.98 (378.96 to 513.01) |
| Day 77 | 363.15 (298.76 to 427.53) | 417.52 (344.23 to 490.81) |
| Day 112 | 320.95 (266.16 to 375.74) | 343.92 (284.63 to 403.20) |
The skin tape strip collection was comprised of 1 set of 15 strips from non-lesional skin and was collected as part of the TEWL skin barrier assessment. The TEWL values measured at every 5 tape strips were used to model the TEWL slope. TEWL slope assesses skin barrier integrity. An increase in TEWL values shows damage to the skin barrier function. TEWL slope is summarized as the mean difference (and corresponding 95% confidence interval) between the dupilumab and placebo arms. The mean difference in slope for each Day is reported from a linear mixed model for repeated measures with a fixed effects for basal TEWL prior to tape stripping, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, tape strip number, and an interaction term between treatment arm and tape strip number.
| g/m^2/hour | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 7 | 1.77 (1.25 to 2.29) | 1.84 (1.18 to 2.51) |
| Day 14 | 1.56 (1.17 to 1.96) | 1.78 (1.28 to 2.28) |
| Day 21 | 1.43 (0.95 to 1.91) | 1.98 (1.37 to 2.60) |
| Day 28 | 1.38 (0.97 to 1.79) | 1.73 (1.23 to 2.23) |
| Day 42 | 1.47 (0.96 to 1.97) | 1.76 (1.15 to 2.37) |
| Day 77 | 1.15 (0.79 to 1.52) | 1.42 (0.99 to 1.85) |
| Day 112 | 1.03 (0.70 to 1.36) | 1.30 (0.94 to 1.67) |
EASI is a composite score (range: 0-72) measuring physical signs of atopic dermatitis, including area of involvement and severity. Severity components include: erythema, papulation, excoriation and lichenification \[0=absent, 1=mild, 2=moderate, 3=severe\] for each body region (head/neck, trunk, arms, legs). Area of involvement (%) is assessed for each body region. Area and severity of each body region is weighted based on size of region, and region scores are added for the total score. Scores ≤7 are considered mild, \>7 and ≤21 are considered moderate, and \>21 are considered severe. The mean EASI score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for EASI at Day 0, treatment arm, clinical site, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s), Additionally, a similar model was fit using all time points.
| units on a scale | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 26.52 (24.21 to 28.83) | 24.60 (21.73 to 27.46) |
| Day 7 | 25.96 (23.56 to 28.36) | 24.92 (21.92 to 27.91) |
| Day 14 | 20.36 (17.92 to 22.81) | 23.13 (20.08 to 26.19) |
| Day 21 | 16.57 (13.98 to 19.16) | 22.75 (19.51 to 25.98) |
| Day 28 | 15.09 (12.47 to 17.72) | 21.67 (18.36 to 24.99) |
| Day 42 | 11.90 (9.10 to 14.70) | 20.40 (16.83 to 23.96) |
| Day 77 | 8.84 (6.67 to 11.00) | 7.54 (4.89 to 10.19) |
| Day 112 | 6.97 (5.19 to 8.76) | 5.53 (3.45 to 7.61) |
Investigator Global Assessment (IGA) score is a subjective scale measuring disease severity. Based on a 5-point scale from 0 (completely clear) to 4 (severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. The mean IGA score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for IGA at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
| units on a scale | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 3.49 (3.34 to 3.64) | 3.28 (3.09 to 3.47) |
| Day 7 | 3.32 (3.18 to 3.45) | 3.28 (3.11 to 3.45) |
| Day 14 | 3.12 (2.96 to 3.28) | 3.16 (2.96 to 3.37) |
| Day 21 | 2.86 (2.67 to 3.05) | 3.20 (2.96 to 3.44) |
| Day 28 | 2.72 (2.52 to 2.92) | 3.28 (3.02 to 3.54) |
| Day 42 | 2.58 (2.36 to 2.81) | 3.24 (2.95 to 3.53) |
| Day 77 | 2.20 (1.92 to 2.48) | 2.20 (1.84 to 2.55) |
| Day 112 | 1.94 (1.63 to 2.24) | 1.89 (1.51 to 2.27) |
SCORAD is a composite index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments of itch and sleep loss \[itch: 0 (no itch) to 10 (worst itch imaginable) / sleep loss: 0 (no sleep loss) to 10 (worst imaginable sleep loss)\], and c) 6 disease intensity assessments \[dryness, erythema, edema/papulation, excoriation, lichenification and oozing/crusting, each graded from 0-3: 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The score ranges from 0 (no AD present) to 103 (severe). The mean SCORAD score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for SCORAD at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
| units on a scale | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 56.91 (53.46 to 60.35) | 53.12 (48.78 to 57.46) |
| Day 7 | 54.78 (51.70 to 57.86) | 54.96 (51.14 to 58.78) |
| Day 14 | 46.55 (43.09 to 50.00) | 52.01 (47.66 to 56.73) |
| Day 21 | 39.40 (35.53 to 43.28) | 51.87 (47.01 to 56.73) |
| Day 28 | 36.34 (32.64 to 40.04) | 50.99 (46.33 to 55.66) |
| Day 42 | 32.22 (28.38 to 36.06) | 51.02 (46.15 to 55.90) |
| Day 77 | 27.63 (23.87 to 31.38) | 28.18 (23.53 to 32.83) |
| Day 112 | 23.92 (20.25 to 27.59) | 25.01 (20.57 to 29.46) |
Pruritus NRS scale is an assessment tool that is used to report the average intensity of a participant's pruritus (itch) during a 24-hour recall period. Participants were asked to report the average itch experienced during the past 24 hours on a scale of 0 - 10 \[0= no itch; 10= worst imaginable itch\]). The mean Pruritus NRS score in each treatment arm is reported from a linear mixed model for repeated measures with fixed effects for Pruritus NRS at Day 0, treatment arm, clinical site, disease severity at Day 0 as measured by EASI ≥ 21.1 or \< 21.1, time point of measurement, and an interaction term between treatment arm and pre-specified time point(s). Additionally, a similar model was fit using all time points.
| units on a scale | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Day 3 | 5.37 (4.73 to 6.01) | 5.64 (4.83 to 6.45) |
| Day 7 | 5.46 (4.83 to 6.09) | 5.48 (4.69 to 6.28) |
| Day 14 | 4.48 (3.91 to 5.05) | 5.29 (4.58 to 6.00) |
| Day 21 | 4.20 (3.62 to 4.79) | 5.22 (4.50 to 5.93) |
| Day 28 | 3.67 (3.07 to 4.28) | 5.14 (4.37 to 5.90) |
| Day 42 | 3.40 (2.79 to 4.01) | 5.18 (4.41 to 5.94) |
| Day 77 | 2.55 (2.05 to 3.05) | 1.88 (1.28 to 2.48) |
| Day 112 | 2.38 (1.83 to 2.94) | 1.95 (1.27 to 2.64) |
16S rRNA microbiome data (e.g., bacterial sequence reads) will be employed to identify changes in community composition and diversity at lesional and non-lesional skin sites prior to and throughout dupilumab or placebo treatment.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on the skin transcriptome in lesional and non-lesional skin. Inclusion in this exploratory aim is restricted to non-University of Rochester Medical Center study participants only.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on gene expression in the skin transcriptome of non-lesional skin.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on the gene expression in the skin transcriptome of lesional skin.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on lipids, which play a role in the skin barrier, will be extracted from the skin tape strips and measured using mass spectrometry methodology. Skin tape strip method allows characterization of components of the epidermis, dermis, and immune cells present in the skin.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on the expression of the bacterium Staphylococcus aureus (S. aureus) superantigens and toxins on lesional and non-lesional skin.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on non-lesional skin barrier structure and Langerhans cells (LC) by confocal imaging. Inclusion in this exploratory aim is limited to University of Rochester Medical Center study participants.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on the function of the skin microbiome (e.g., the ability of Coagulase-negative staphylococci isolates \[CoNS\] to kill S. aureus) in lesional and non-lesional skin.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on PBMC immunoprofiles.Flow cytometry analysis will be performed on PBMCs, using phenotyping panels to identify resting leukocyte populations, as well as T cell responses to antigens and myeloid responses to Toll-like receptor (TLR) ligands.
Results for this outcome have not been posted.
The aim is to assess the effect of dupilumab on serum biomarkers (e.g. T helper type 2 \[Th2\] biomarkers).
Results for this outcome have not been posted.
The presence of anti-drug antibodies will be assessed and compared between intervention groups.
Results for this outcome have not been posted.
Towards discovery and replication of susceptibility loci in atopic dermatitis pathogenesis.
Results for this outcome have not been posted.
Collected over Up to 182 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab+Open Label Extension and Follow-Up | 0/46 (0%) | 1/46 (2.2%) | 27/46 (58.7%) |
| Placebo+Open Label Extension and Follow-Up | 0/26 (0%) | 0/26 (0%) | 17/26 (65.4%) |
| Event | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Intentional overdoseInjury, poisoning and procedural complications | 1/46 | 0/26 |
| Schizoaffective disorder bipolar typePsychiatric disorders | 1/46 | 0/26 |
| Event | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up |
|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 7/46 | 7/26 |
| EczemaSkin and subcutaneous tissue disorders | 12/46 | 5/26 |
| HeadacheNervous system disorders | 1/46 | 4/26 |
| Upper respiratory tract infectionInfections and infestations | 7/46 | 3/26 |
| NasopharyngitisInfections and infestations | 6/46 | 2/26 |
| ConjunctivitisInfections and infestations | 4/46 | 3/26 |
| FallInjury, poisoning and procedural complications | 1/46 | 3/26 |
| Skin abrasionInjury, poisoning and procedural complications | 1/46 | 3/26 |
| PruritusSkin and subcutaneous tissue disorders | 4/46 | 3/26 |
| Dry eyeEye disorders | 4/46 | 1/26 |
Modified intent-to-treat (mITT): All participants who were randomized and have Staphylococcus aureus (S. aureus) abundance measured at Day 0 and Day 28.
| Age, Continuous(years) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Mean | 36.6 ± 15.56 | 37.3 ± 15.61 | 36.8 ± 15.47 |
| Sex: Female, Male(Participants) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Female | 17 | 7 | 24 |
| Male | 28 | 19 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 39 | 22 | 61 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 7 | 7 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 3 | 11 |
| White | 21 | 13 | 34 |
| More than one race | 5 | 1 | 6 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(Participants) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| United States | 45 | 26 | 71 |
| Body Weight(kilograms (Kg)) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Mean | 80.7 ± 19.45 | 79.4 ± 18.58 | 80.2 ± 19.01 |
| Height(centimeters (Cm)) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Mean | 170.9 ± 9.27 | 175.3 ± 11.74 | 172.5 ± 10.38 |
| Body Mass Index (BMI)(Kg/m^2) | Dupilumab+Open Label Extension and Follow-Up | Placebo+Open Label Extension and Follow-Up | Total |
|---|---|---|---|
| Mean | 27.5 ± 5.69 | 25.7 ± 4.90 | 26.9 ± 5.45 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Apr 2020, 20 months.
Results were first posted in Jun 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab
National Institute of Allergy and Infectious Diseases (NIAID) →